BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $60 from $65 and keeps a Buy rating on the shares. The firm’s management team meetings after the “surprising” Freenome deal has left it more positive for the outlook of both companies, the analyst tells investors in a research note. Exact Sciences has pivoted very quickly from its setback in its own blood program and de-risked to some extent the threat of blood-based competition from Guardant Health (GH), the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences price target lowered to $60 from $70 at Piper Sandler
- Cathie Wood Makes a $69M Bet on Exact Sciences; Sells Palantir, Roblox, and DraftKings
- Exact Sciences Corp’s Strong Earnings Call Highlights
- Exact Sciences: Strong Financial Performance and Strategic Initiatives Justify Buy Rating
- Exact Sciences price target lowered to $66 from $75 at TD Cowen